Antineoplastic Agents
Research News and Information

Sunday, November 08, 2009

Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.

29 Nov 2009 Lonafarnib is a potent, selective farnesyltransferase inhibitor (FTI) undergoing clinical studies for the treatment of solid tumors and hematological malignancies. Preclinically, a number of FTIs, including lonafarnib, interact with taxanes to ... Read more...

Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel.

29 Nov 2009 It has recently been shown that docetaxel chemotherapy is effective in prolonging life in patients with prostate cancer (PCa). We have investigated potential ways of increasing the effectiveness of chemotherapy in this disease. We have previously ... Read more...

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.

29 Nov 2009 BACKGROUND: Despite the increasing cure rates for children with acute lymphoblastic leukemia (ALL), patients who relapse continue to have poor prognosis. The Children's Oncology Group (COG) conducted a limited institution Phase II trial of ... Read more...

Latest indexed articles for 'Antineoplastic Agents'

These are the very latest articles for this heading:

• Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. 29 Nov 2009
• Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel. 29 Nov 2009
• A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. 29 Nov 2009
• The beneficial role of gonadotropin releasing hormone agonists on fertility preservation. 29 Nov 2009
• Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant. 29 Nov 2009
• Monitoring of ototoxicity in young children receiving carboplatin for retinoblastoma. 29 Nov 2009
• Restriction of cisplatin induction of acute apoptosis to a subpopulation of cells in a three-dimensional carcinoma culture model. 13 Nov 2009
• Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. 13 Nov 2009
• Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants. 13 Nov 2009
• Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. 13 Nov 2009
• Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. 30 Oct 2009
• The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells. 30 Oct 2009
• Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. 30 Oct 2009
• Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. 30 Oct 2009
• Have we reached a plateau in adjuvant breast cancer therapy? 22 Oct 2009
• Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. 20 Oct 2009
• Chronic natural killer-cell lymphocytosis successfully treated with alemtuzumab. 13 Oct 2009
• Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer cells. 13 Oct 2009
• Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma. 11 Oct 2009
• Cancer research. Looking for a target on every tumor. 7 Oct 2009

See a longer list of these articles.

Technical information about 'Antineoplastic Agents'

Definition: Substances that inhibit or prevent the proliferation of NEOPLASMS.

Registry Number: 0

Descriptor UI: D000970

Alternative terms: Antineoplastic Agents; Agents, Antineoplastic; Antineoplastics; Antitumor Drugs; Drugs, Antitumor; Antineoplastic Drugs; Drugs, Antineoplastic; Antitumor Agents; Agents, Antitumor;

Related Mesh Headings: Cytotoxins; Infusions, Intra-Arterial; Chemotherapy, Cancer, Regional Perfusion; Tumor Lysis Syndrome; Chemoembolization, Therapeutic; Anticarcinogenic Agents;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.248;

Technical Notes: /admin: various administration procedures are available, as CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CHEMOEMBOLIZATION, THERAPEUTIC and INFUSIONS, INTRA-ARTERIAL; for combined anticancer agents, ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS is available; Manual 24.4.2.1+